Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cellivery IPO To Fund Potential First-In-Class Parkinson's Asset, May Speed Licensing Deal

Executive Summary

Marking the first Korean company to launch an initial public offering on the recommendation of its lead broker, Cellivery Therapeutics is slated to use the upcoming proceeds to progress preclinical trials of its lead assets for Parkinson's disease and pancreatic cancer, which the company aims to license out to global partners in the early development stages.


Related Content

Ildong, Cellivery To Co-Develop Novel Biologic For Parkinson's


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts